Elfabrio

Active Ingredient(s): Pegunigalsidase Alfa-iwxj
FDA Approved: * May 9, 2023
Pharm Company: * CHIESI FARMACEUTICI SPA
Category: Genetic Disorders
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Elfabrio 20 mg/10ml Intravenous Injection, Solution, Concentrate
NDC: 10122-160
Labeler:
Chiesi USA, Inc.
Elfabrio 5 mg/2.5ml Intravenous Injection, Solution, Concentrate
NDC: 10122-165
Labeler:
Chiesi USA, Inc.